Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to announce the significant achievements of its IsoPet ® Animal Cancer Division, setting new milestones in veterinary cancer care, and expanding its network of certified clinics across the U.S. IsoPet ® 2024: A Year of Innovation and Expansion In 2024, IsoPet ® cemented its position as a leader in minimally invasive animal cancer treatments,... Read More

Richland, WA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- – Vivos Inc. (OTCQB: RDGL) proudly announces the initiation of its first human clinical trial for RadioGel ® Precision Radionuclide Therapy™ in India. This milestone trial, which has commenced with the successful treatment of five patients with cancerous lymph nodes, represents a transformative step in advancing innovative cancer therapies. This initial trial in India closely... Read More

Richland WA N, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Certifies new clinic for IsoPet therapy. NorthStar Vets - Veterinary Emergency & Trauma Specialty Center in Robbinsville, NJ. provides 24/7/365 emergency, trauma, and critical care and a suite of veterinary specialty services for small animals. They have been approved and licensed to offer IsoPet Precision Radionuclide Therapy as a cancer... Read More

Richland WA N, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. We recently treated our first exotic animal, a ferret, with encouraging results, seeing a considerable reduction in tumor size after three weeks. Treatment options for cancer in small exotic animals remain limited, and the current standard of care—surgical tumor removal—can be too invasive for exotic animals. Dr. Korenko commented, “While... Read More

Richland WA, July 29, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides IDE Submission Status Update. The FDA has been working diligently to review the extensive amount of material that we provided in our IDE submission within the 30-day statutory time limit. We have been in regular communication with the FDA and provided responses to five sets of Interactive Review Requests. Based on our communication with the FDA... Read More

Richland WA, June 28, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”). The filing was an amendment, addressing the FDA comments to our previous application (Q211938/S001). Today’s IDE submission marks our first filing with the FDA following the grant of the FDA Breakthrough Device Designation for the Radiogel ™ Precision Radionuclide Therapy.... Read More

Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program. Dr. Mike Korenko stated “We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data... Read More

Richland WA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that it certified three additional clinics to offer Isopet ® Precision Radionuclide Therapy (PRT). The three new clinics are The Myhre Equine Clinic , located in Rochester, New Hampshire, the Hopkinton Animal Hospital , located in Weare, New Hampshire and the Indian Creek Veterinary Hospital , located in Fort Wayne,... Read More

Richland WA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that the company filed a utility patent application on a range of particles for precision radionuclide therapy as a follow-up to its provisional patent filed on 1/15/2022. This patent was filed in the USA and internationally via the Patent Cooperation Treaty, PCT. This includes Canada, the European Union, Japan, Australia,... Read More

Richland WA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that they filed a provisional patent application on the system equipment to support precision radionuclide therapy. This includes the shipping containers, the shielded vial holder, the Peltier chiller, and the syringe shields. These device designs are integrated into our production standardization effort. They can be used for... Read More